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Skeletal muscle atrophy or wasting accompanies various chronic illnesses and the aging
process, thereby reducing muscle function. One of the most important components
contributing to effective muscle repair in postnatal organisms, the satellite cells (SCs),
have recently become the focus of several studies examining factors participating in
the atrophic process. We critically examine here the experimental evidence linking
SC function with muscle loss in connection with various diseases as well as aging,
and in the subsequent recovery process. Several recent reports have investigated the
changes in SCs in terms of their differentiation and proliferative capacity in response to
various atrophic stimuli. In this regard, we review the molecular changes within SCs that
contribute to their dysfunctional status in atrophy, with the intention of shedding light on
novel potential pharmacological targets to counteract the loss of muscle mass.
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Introduction
Skeletal muscle atrophy is characterized by a loss of muscle mass and force, that occurs in response
to a variety of pathological and physiological stimuli such as aging, cancer, chronic kidney disease
(CKD), chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), diabetes,
AIDS infection, sepsis, burns, muscle disuse, loss of muscle innervation, malnutrition, steroid-
induced catabolic stimulation, and different congenital neuromuscular diseases (Bonaldo and
Sandri, 2013; Egerman and Glass, 2014; Cohen et al., 2015). Loss in muscle mass is characterized
by a decrease in cross-sectional area of muscle fibers, that is primarily the outcome of a preferential
increase in intracellular protein degradation over protein synthesis (Bonaldo and Sandri, 2013;
Egerman and Glass, 2014; Cohen et al., 2015). In most muscle wasting conditions, the loss of
muscle tissue is not homogeneous, displaying differential effects on specific muscle groups and
impacting distinct fiber types (Ciciliot et al., 2013). In specific forms of atrophy, such as age-related
atrophy (sarcopenia), the reduction in fiber size is also accompanied by a reduction in the number
of fibers, further highlighting the heterogeneity of the atrophying process occurring in different
muscle wasting conditions (Lexell et al., 1988).
Muscle fibers are post-mitotic syncytia formed by the fusion of several hundreds of myogenic
progenitors during pre- and post-natal development (Biressi et al., 2007). A majority of the
myonuclei are added to developing fibers during post-natal growth, when there is a dramatic
increase in muscle mass (Zhang et al., 1998). Not all myogenic progenitors terminally
differentiate into muscle fibers during development, but a fraction of them remains in the
adult muscles as a pool of undifferentiated myogenic stem cells. Different cellular types that
possess the ability to differentiate into muscle fibers have been identified (Cossu and Biressi,
2005; Peault et al., 2007). Nevertheless, a population of stem cells, called ‘‘satellite cells’’ (SCs),
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due to the peculiar anatomical location between the fiber
sarcolemma and the basal lamina surrounding the fiber, is
believed to contribute in a major way to post-natal growth
and muscle repair upon injury (Schultz, 1996; Lepper et al.,
2011; Murphy et al., 2011; Sambasivan et al., 2011). In healthy
adult muscles, SCs are largely quiescent, but can be activated by
appropriate stimuli in the form of injury or exercise, resulting
in regeneration and possibly further growth (hypertrophy) of
the muscle tissue (Zammit et al., 2006; Schiaffino and Partridge,
2008). Several studies have investigated the role played by SCs in
muscle hypertrophy and conclusions drawn from these studies
are equivocal (Blaauw and Reggiani, 2014). A key role for
SCs in the hypertrophic response is supported by observations
that SCs are consistently activated in hypertrophic models and
that their elimination by irradiation severely blunts overload-
induced muscle hypertrophy (Rosenblatt et al., 1994). On the
contrary, various observations using mutant mice to genetically
ablate SCs and induce hypertrophy indicate that SC functionality
does not constitute an absolute requirement in initiating muscle
hypertrophy, suggesting that the prerequisite nature of their
involvement might be limited to later stages in stabilizing the full
hypertrophic response on a long-term basis (Amthor et al., 2009;
Blaauw et al., 2009; McCarthy et al., 2011; Lee et al., 2012; Fry
et al., 2014).
Whereas our knowledge of SC behavior in muscle
hypertrophy is rapidly increasing, the role played by SCs
during muscle atrophy remains largely enigmatic. Recent reports
have generated an active debate in the scientific community
on the active participation of SCs in the atrophic response, or
whether muscle fiber alterations exclusively account for atrophy.
In this manuscript, we review the experimental evidence
supporting either view.
Several studies have investigated the effects of atrophic stimuli
on muscle fibers and have identified key signaling pathways
operating within the fiber that contribute to a decrease in fiber
cross-sectional area. These studies highlighted the importance of
protein homeostasis in regulatingmusclemass, and identified the
ubiquitin-proteasome and the autophagy-lysosome machineries
as the twomost important protolithic systems controlling protein
turnover in muscle fibers. Several recent reviews describe the
advances in understanding signaling mechanisms controlling
the activity of these two systems in skeletal muscle fibers
(Sandri, 2013; Schiaffino et al., 2013). In this review, we focus
on the signaling pathways triggered in SCs in response to
various atrophic stimuli. Moreover, we review the studies that
address whether these molecular changes can be suppressed
or reversed to induce SCs to increase the mass of atrophied
muscles.
Does SC Activity Affect the Loss of Muscle
Mass?
Muscle homeostasis depends on a fine balance between
catabolism and anabolism. A large body of evidence indicates
that alterations in the control of protein turnover modify this
balance and play an important role in essentially all forms of
muscle atrophy (Sandri, 2008). Nevertheless, the mass of every
tissue, including skeletal muscle is not only dependent on protein
turnover, but also on cellular turnover (Sartorelli and Fulco,
2004). In keeping with this, muscle fibers are lost in certain
forms of muscle wasting (Lexell et al., 1988). Moreover, muscle
fibers are multinucleated structures, and it has been proposed
that there are distinct ‘‘myonuclear domains’’, whereby each
myonucleus governs the surrounding cytoplasm by producing
enough protein to support only a limited portion of the fiber
(Mitchell and Pavlath, 2004). Although some studies report a
reduction in muscle fiber size without a change in myonuclear
number (Wada et al., 2002; Gundersen and Bruusgaard, 2008),
several reports have documented a decrease in the number of
myonuclei accompanying different forms of atrophy, supporting
the hypothesis that myonuclear turnover and a reduction in
muscle mass are causally related (Darr and Schultz, 1989;
Schmalbruch et al., 1991; Allen et al., 1995, 1996; Day et al.,
1995; Hikida et al., 1997). More importantly, this raises the
prospect that alterations in myonuclear turnover can stabilize
the reduction in muscle mass, at least under certain atrophic
conditions.
As myonuclei are postmitotic, the need to replenish lost
myonuclei to maintain a constant myonuclear number must
come from myogenic progenitors that are able to fuse with
the fibers. SCs, which have been reported to contribute to a
large fraction of the fiber myonuclei during regeneration and
growth, represent a natural candidate for this role (Moss and
Leblond, 1971). In keeping with this idea, ablation of SCs in a
paired box protein (Pax7)DTR knock-in mouse model revealed
a 20–40% loss of muscle mass 2 weeks after intramuscular
injection of diphtheria toxin, an effect that persisted for 7
weeks after SC elimination and was exacerbated with strenuous
resistance exercise (Sambasivan et al., 2011). Another study
demonstrating an essential role for miRNAs in SC quiescence
observed mild muscle atrophy within 6 months in uninjured
mice that expressed a SC-specific conditional knockout (KO)
of the gene Dicer (Cheung et al., 2012). These reports raise the
tantalizing possibility that despite a low turnover rate in healthy
muscle (Spalding et al., 2005), SCs could have an impact on
homeostatic control of muscle mass. In contrast, a study using a
genetic approach that allows for long-term depletion of SCs upon
tamoxifen intraperitoneal injection in sedentary mice challenges
this view (Fry et al., 2015). Despite the low regenerative capacity,
these mice do not present signs of atrophy in hind limb muscles
1 month after tamoxifen administration and do not display
exacerbated atrophy in 2-year-oldmice. Therefore, these findings
suggest that skeletal muscles do not necessarily require stem
cell participation for tissue maintenance, at least under non-
stressful conditions (Fry et al., 2015). Intriguingly, in a recent
study, SCs were genetically labeled in adult mice and their
fusion to myofibers in the absence of injury was followed
throughout the lifespan of the mice. These experiments showed
a contribution of SCs to myofibers in all muscles considered,
although the extent and timing of their involvement differed in
distinct muscles (Keefe et al., 2015). Importantly, the ablation
of SCs using a genetic approach similar to that used by Fry
et al. (2015) also showed a muscle group-specific response. In
corroboration with the Fry et al. (2015) data, limb muscles were
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not significantly affected 6 months after SC depletion (Keefe
et al., 2015). However, the diaphragm and extra ocular muscles
displayed smaller fibers after 6 months of depletion of SCs, a
decrease that was not exacerbated at later time-points (Keefe
et al., 2015). Although a possible explanation for the different
results derived from the individual studies could depend on
the different nature of the animal models and experimental
settings employed, the different types of muscles analyzed, or on
the potential stress derived from the intramuscular injection of
diphtheria toxin (Sambasivan et al., 2011), further investigations
appears to be necessary to clarify the role of SCs in muscle
homeostasis.
The discussion on the role played by SCs in the homeostatic
maintenance of mass in healthymuscles has broader implications
for the study of SC involvement in counteracting muscle mass
loss under atrophying stimuli. The long-term SC depletion study
conducted by Fry and colleagues, whereby the absence of SCs
did not exacerbate sarcopenia in 2-year-old mice, is suggestive
of the notion that SCs do not exert a compensatory action
to counteract atrophy with age (Fry et al., 2015). Despite the
compelling observations made in this study, the conclusions
could possibly be limited by the incomplete depletion of SCs
obtained in aged mice (an average of ∼83%; Fry et al., 2015).
Notably, elimination of ∼85% of SCs by freeze- or cardiotoxin-
mediated injury still results in muscle regeneration (Gayraud-
Morel et al., 2007). Therefore, it is particularly relevant that the
study from Keefe and colleagues using a mouse strain which
allowed for the ablation of >95% of the SCs, obtained results
that were similar to those reported by Fry and colleagues. When
mice depleted of SCs were analyzed at 20 months of age, the
contribution of SCs to myofiber maintenance appeared to be
minimal in most hind limb muscles, with the striking exception
of extensor digitorum longus (EDL) muscles that displayed a
∼15% decline in fiber size (Keefe et al., 2015). Although an
age-related reduction in fiber cross-sectional area is apparent at
20 months of age in most muscles, it is mainly after 2 years
that a dramatic loss of muscle mass occurs in mice, which
correlates with the appearance of an irreversible pre-senescent
state in SCs that prevents activation and expansion (Sousa-
Victor et al., 2014). The appearance of severe sarcopenia in older
mice opens up the possibility for a primary requirement for SC
contribution at later stages. Therefore, it would be interesting
to extend the ablation studies to mice older than 2 years of
age.
Intriguingly, several reports indirectly suggest that SCs may
play a role in ameliorating sarcopenia, and that sarcopenia
could be at least in part, a consequence of defective SC
function. Several changes affecting the SC compartment have
been observed in aged muscles (Alway et al., 2014). Strikingly,
stem cell function and consequently regenerative potential
are severely affected by aging in different tissues, including
skeletal muscle (Liu and Rando, 2011). Alterations in the
muscle and systemic environment occur during the aging
process, thereby contributing to reversible and irreversible
changes in SCs (Brack and Rando, 2007; Jang et al., 2011;
Sousa-Victor et al., 2015). Moreover, despite the lack of a
clear consensus, a reduction in SC number has been reported
during aging, and it has been correlated with a reduction
in fiber myonuclear content (Brack et al., 2005). Presence of
centrally-nucleated fibers and an up-regulation of Myogenic
differentiation (MyoD), Myogenin and embryonic Myosin
Heavy Chain expression, which are generally considered as
hallmarks of fiber regeneration, have also been documented
in aging muscle (Edström and Ulfhake, 2005). Notably,
a loss of myonuclei with aging in MyoD KO mice was
exacerbated compared to wild-type mice. Since SCs display
defective differentiation in the absence of MyoD expression, this
observation has been interpreted as evidence in favor of a role for
SCs in replenishing fiber myonuclei during aging (Brack et al.,
2005).
An up-regulation of MyoD expression has also been
documented in other forms of atrophy, and is particularly well
established in denervation models of atrophy (Legerlotz and
Smith, 2008). Upon denervation, SCs proliferate transiently,
but do not progress through differentiation and form small
immature (embryonicMyosin Heavy Chain+ve) fibers, indicative
of an unsuccessful attempt to restore muscle mass and
function (Viguie et al., 1997; Borisov et al., 2005; Doppler
et al., 2008). As in aging muscle, the increase in MyoD
expression observed in denervated muscle could be interpreted
as a result of SC activity. Nevertheless, it is notable that
muscle fibers also express MyoD at low levels, even in the
absence of ongoing regeneration (Hughes et al., 1993). It
is therefore possible that the increase in MyoD expression
in muscle observed after denervation, and possibly in other
models of atrophy as well, could constitute a SC-independent
response of the fibers to atrophic stimuli (Koishi et al.,
1995). Indeed it has been proposed that the induction
of MyoD could represent an attempt by muscle fibers to
regain sensitivity to neural activity. In keeping with this
idea, MyoD has been shown to regulate the expression of
Acetylcholine receptor (AChR), the expression of which is
also increased upon denervation (Legerlotz and Smith, 2008).
On similar lines, Myogenin is also expressed in fibers in the
absence of a regenerative response (Hughes et al., 1993), and
can act as an essential mediator of neurogenic atrophy by
regulating the expression of Murf1 and Atrogin-1 within the
fiber, thereby promoting muscle proteolysis (Moresi et al.,
2010).
Alterations in themyogenic program have also been described
in cachexia, a complex metabolic syndrome characterized by
a loss of muscle mass, which is initiated by underlying
illnesses of different nature, such as cancer, CHF, COPD,
CKD, burns, chronic infection and sepsis (Evans et al., 2008;
Fearon et al., 2012). Changes in the expression of myogenic
factors and impaired differentiation have been reported in
cachectic muscles (Coletti et al., 2005; Langen et al., 2006;
Schwarzkopf et al., 2006; Penna et al., 2010; Zhang et al., 2010a;
Wu et al., 2013). In tumor-bearing mice that recapitulated
clinical features of cancer-induced cachexia, as well as in muscle
biopsies from patients with pancreatic cancer, a significant
expansion of cells expressing high levels of the SC-marker
Pax7 was observed (Penna et al., 2010; He et al., 2013).
Intriguingly, the majority of the Pax7+ve cells were noted
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in the interstitium and a fraction of them were reported
to express mesenchymal (Pdgfr-α, Sca1) and pericyte (NG2)
markers, which are not expressed in the SC lineage (He et al.,
2013). These data reveal that cancer-induced atrophy triggers
myogenic commitment in multiple stem cell progenitors, in
addition to the SC population (He et al., 2013). In stark
contrast with other atrophy models (see above), MyoD and
Myogenin expression are not significantly induced in tumor-
bearing mice compared to controls, and an impaired myogenic
program prevents these cells from efficiently fusing with
existing myofibers and therefore ameliorating the wasting
condition (He et al., 2013). Pax7 has been reported to inhibit
differentiation by suppressing MyoD and Myogenin expression
(Olguin and Olwin, 2004). Positive or negative modulation
of Pax7 expression in cachectic mice impact muscle mass
in a negative or positive manner, respectively. Moreover,
depletion of Pax7+ve cells further exacerbated muscle loss,
directly indicating that stem cells are able to counteract
muscle atrophy in cachectic mice. Nevertheless, the persistent
expression of Pax7 stalls the myogenic program and limits
the functionality of muscle stem cells (He et al., 2013).
In line with the idea that SC functionality can compensate
for the effects of atrophic stimuli, mdx mouse models of
Duchenne muscular dystrophy (DMD) showed a correlation
between muscle mass and alterations in regenerative potential.
Specifically, during early stages of pathology characterized by
effective regeneration, a compensatory hypertrophy has been
observed. However, at later stages when regeneration becomes
defective, there is a dramatic decrease in muscle mass (Mouisel
et al., 2010).
Alterations in SC function, including defective fusion
properties, have also been observed in the hind limb suspension
model of disuse atrophy (Mitchell and Pavlath, 2004).
Conversely, changes in SC numbers are not a consistent finding
in disuse atrophy, reflecting the complexity of events occurring in
this context (Brooks and Myburgh, 2014). Notably, the decrease
in muscle mass accompanying different pathophysiological
conditions displays variable changes in SC numbers depending
on the type and the severity of the atrophic stimulus (Table 1).
Also the time-scale of the analysis appears to play an important
role in SC quantification, as highlighted in denervation
experiments, in which an initial phase of proliferation is followed
by a decrease in numbers of SCs (Viguie et al., 1997). The
inconsistent reports on changes in SC numbers, together with
the observations that alterations in SC function appear to be a
common feature in most atrophic conditions, raises the prospect
that rather than absolute numbers, it is the functionality of
the SCs that is more relevant in their ability to counteract
atrophy. Further studies will be required to confirm this
view, and to conclusively impart a non-redundant role for
SCs and other muscle resident stem cells in specific atrophic
processes.
Molecular Alterations in SCs During
Atrophy
It is increasingly becoming clear that distinct signaling
pathways mediate a common outcome of a loss of muscle
mass observed in instances of atrophy, sarcopenia, or cachexia
(Glass, 2005; Fanzani et al., 2012). While the involvement
of these molecular mechanisms has been described in great
detail in myofibers in response to atrophic stimuli (Bonaldo
and Sandri, 2013; Schiaffino et al., 2013), in this section
we review alterations in these pathways occurring in SCs
accompanying fiber atrophy. Moreover, we focus on studies
reporting functional changes in SCs resulting from alterations
in these pathways, which possibly contribute to the loss
of muscle mass. Importantly, these pathways extensively
modulate one another and coordinate overlapping responses
not only in the muscle fiber, but also in the SC compartment
(Figure 1). Below, we discuss five major signaling pathways
traditionally associated with skeletal muscle atrophy: (a)
insulin-like growth factor (IGF)-Akt-FoxO signaling; (b)
Transforming Growth Factor Beta (TGFβ) superfamily
signaling; (c) Glucocorticoids and androgen signaling; (d)
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) signaling; (e) Sirtuin 1 (Sirt1) signaling and
mitochondrial dysfunction. Additionally, we review recent
TABLE 1 | Satellite cell alterations in different atrophic conditions.
Condition Changes in number Changes in function Notes References
Aging ↓ = Yes ↓ proliferation Snijders et al. (2009) and Alway et al. (2014)
↓ myogenic differentiation
Cachexia ↑ Yes ↑ activation/proliferation Penna et al. (2010) and He et al. (2013)
↓ differentiation/fusion
Denervation ↑ ∗ Yes ↑ activation/proliferation Viguie et al. (1997), Borisov et al. (2005) and
↓ fusion Doppler et al. (2008)
Hind limb suspension ↓ = ↑ Yes ↓ proliferation Mitchell and Pavlath (2004)
↓ differentiation Brooks and Myburgh (2014)
Glucocorticoids n.d. Yes ↓ proliferation Dong et al. (2013)
↓ differentiation
DMD ↑ Yes ↓ proliferation Blau et al. (1983) and Delaporte et al. (1984)
↓ myogenic Jasmin et al. (1984),
differentiation/fusion Melone et al. (1999) and Biressi et al. (2014)
↑, Increase; ↓, decrease; =, unchanged; n.d., not defined; * initial increase, but reduced in the long-term (Viguie et al., 1997).
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studies involving (f) Notch signaling, a pathway well known
to influence SC functionality for a role in regulating muscle
mass.
IGF-Akt-FoxO Signaling
A central pathway regulating fiber size is the IGF-Akt pathway
(Rommel et al., 2001). Activation of this pathway triggers the
activation of mammalian target of Rapamycin (mTOR) that
results in the phosphorylation of its targets p70 S6K and 4E-BP1
(Bodine et al., 2001; Pallafacchina et al., 2002; Wullschleger et al.,
2006). An additional consequence of these growth- promoting
stimuli is the inhibition of the FoxO family of transcription
factors that are key in initiating the atrophy program (Sandri
et al., 2004). Consistent with this finding, components of
the FoxO pathway were found to be increased in skeletal
muscle during sepsis, cancer cachexia, and treatment following
lipopolysaccharide (LPS), glucocorticoid, and cytokines (Liu
et al., 2007; Schmitt et al., 2007; Crossland et al., 2008; Moylan
et al., 2008). Additionally, the ability of the FoxO transcription
factors to regulate muscle mass during disuse atrophy and
following glucocorticoid treatment via the regulation of atrophy-
related genes has been well documented (Kamei et al., 2004;
Lecker et al., 2004; Sandri et al., 2004; Senf et al., 2010).
Only recently have studies begun to address the influence
of IGF1 signaling in the behavior of SCs accompanying the
atrophic response in fibers. For instance, in CKD-induced
muscle atrophy, SCs displayed a reduction in phosphorylated
Akt levels indicative of impaired IGF-1 signaling, and a decrease
in activation and myogenic progression (Zhang et al., 2010a).
Moreover, both CKD and IGF-1 receptor KO mice developed
fibrosis in regenerating muscles, suggesting a decline in SC
functionality (Zhang et al., 2010a). Similarly, old dystrophic
mdx mice also displayed reduced Akt phosphorylation along
with defective regeneration and atrophy (Mouisel et al., 2010).
In studies aimed at addressing the role of the FoxO’s in SCs,
overexpression of FoxO3 in myogenic progenitors decreased
their proliferation (Rathbone et al., 2008). Similarly, abolishing
FoxO activity either by injecting dominant negative (DN)
FoxO-expressing plasmid into murine muscles or deleting the
Foxo3 gene specifically in SCs, resulted in an increase in the
proliferation of SCs (Reed et al., 2012; Gopinath et al., 2014).
Interestingly, the former study reported a hypertrophic response
following global suppression of FoxO activity, which acts as a
protective mechanism to suppress atrophy following sepsis and
cancer (Reed et al., 2012). However, while FoxO functionality
may support atrophy when expressed in the fiber, the expression
of a specific isoform, FoxO3, in SCs seems to be a prerequisite
for maintaining the regenerative capacity of muscle and might
therefore act to protect the muscle from atrophying stimuli
(Gopinath et al., 2014). These paradoxical observations suggest
that FoxO activity promotes different programs in SCs vs. fibers,
and underscores the importance of identifying the biochemical
processes that promote atrophy in combination with a SC-
focused approach.
FIGURE 1 | Overview of the signaling pathways in satellite cells
(SCs) during atrophy. Schematic representation of the major
signaling pathways implicated in SC biology under different atrophic
stimuli (see text for details). Cross-talks between different pathways
are highlighted by positive and negative regulation at different levels.
Abbreviations: AR, androgen receptor; GR, glucocorticoid receptor;
Il-6R, Interleukin-6 receptor; IGF-1R, IGF-1 receptor; LIFR, LIF
receptor; AT1R, Angiotensin II receptor 1; ActRII, Activin receptor 2;
Fst, Follistatin; Mst, Myostatin; NICD, Notch intracellular domain; MT,
mitochondria.
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TGFβ Superfamily Signaling
Members of the TGFβ superfamily are potent regulators of
muscle mass (Goodman and Hornberger, 2014). Canonical
TGFβ signaling operates through the Smad signaling cascade.
Specifically, the TGF-βs, Activins, and some members of
the growth differentiation factor (GDF) subfamilies activate a
Smad2/3-dependent signaling cascade, whereas members of the
bone morphogenetic protein (BMP) subfamily primarily induce
a Smad1/5/8-dependent signaling mechanism (Massagué, 1998).
An increasing amount of evidence has implicated Smad2/3 in
possessing a catabolic function, while Smads 1/5/8 have an
anabolic function (Goodman and Hornberger, 2014). Members
of the TGFβ superfamily play an important role in controlling
the proliferation and differentiation of myogenic cells, suggesting
that the effects exerted on muscle mass are in part achieved by
controlling SC function (Kollias and McDermott, 2008).
Myostatin (GDF8), is a member of the TGFβ superfamily
and a potent inhibitor of muscle growth, such that various
mammalian species bearing Myostatin-null mutations display
a hypertrophic response (Kambadur et al., 1997; Lee and
McPherron, 2001; Schuelke et al., 2004). Myostatin binding to
Activin receptor 2 (ActRII) and Activin receptor-like kinase
4 and 5 (ALK 4/5) activates the Smad2/3-dependent signaling
cascade and blocks the Akt-mTOR growth- promoting pathway
(Rommel et al., 2001). Systemic administration of Myostatin
in adult mice was found to induce profound muscle loss
(Zimmers et al., 2002). Moreover, enhanced levels of Myostatin
have been observed in a variety of muscle wasting conditions
(Gonzalez-Cadavid et al., 1998; Lalani et al., 2000; Yarasheski
et al., 2002; McKay et al., 2012). Importantly, Myostatin was
suggested to play a role in negatively regulating SC activity
by inhibiting myogenic progression (Langley et al., 2002;
McCroskery et al., 2003; McFarlane et al., 2008; Trendelenburg
et al., 2009). Consistent with the notion that modulation of
Myostatin expression is bound to have a significant impact on
muscle mass and SC behavior, it was found that inhibition of
the ActRIIB pathway stimulated SC proliferative potential and
reversed muscle wasting in cancer-bearing mice (Zhou et al.,
2010). Moreover, altered levels of Myostatin and its receptor
resulted in impaired SC proliferation and differentiation in
muscle wasting accompanying liver cirrhosis in a portacaval
anastomosis (PCA) rat model (Dasarathy et al., 2004). While it
has been suggested that a loss in body weight of the PCA rats
compared to sham controls is an overall consequence of specific
fiber type atrophy (type 2) and impaired SC functionality, what
remains to be determined is a quantitative assessment of SC
dysfunction alone that contributed to the atrophy observed in
this model.
Several studies have provided insights into mechanisms
operating upstream and downstream of Myostatin, thereby
identifying diverse signaling pathways that have a shared
outcome of a loss of muscle mass. Indeed, it has been shown
that Numb, a mediator of asymmetric cell division suppresses
Myostatin expression, such that Numb-deficient SCs display
impaired proliferation characterized by high levels of p21 and
Myostatin (George et al., 2013). A decrease in muscle mass
was apparent after developmental deletion of Numb (George
et al., 2013). Given these results, it would then be interesting to
investigate whether SC-specific Numb conditional KO animals
display a reduction in muscle mass, and if the loss is exacerbated
in the background of liver cirrhosis, cancer cachexia or other
muscle wasting conditions. Intriguingly, lower levels of Numb
expression have been reported inmuscle biopsies from oldermen
(60–75 years old) than in muscles from younger men (18–25
years old; Carey et al., 2007).
Recent reports have implicated a role for Stat3, a downstream
effector of Interleukin 6 (IL-6) in muscle wasting (Muñoz-
Cánoves et al., 2013; Zhang et al., 2013). IL-6, an inflammatory
cytokine is itself known to be involved in initiating muscle
wasting when present systemically and for sustained periods of
time (Strassmann et al., 1992; Haddad et al., 2005). Elevated levels
of activated Stat3 (p-Stat3) were shown to initiate Myostatin-
mediated muscle wasting and inflammation in patients with
CKD or diabetes via increase in C/EBP δ levels (Zhang et al.,
2013). Consistent with this, muscle-specific deletion of Stat3
and inhibition of CCAAT/enhancer-binding protein gamma
(C/EBP δ) expression countered the loss of muscle mass in CKD
(Zhang et al., 2013). While this study did not address the status of
the Stat3 pathway and the consequences of its modulation within
SCs, another study demonstrated that conditional ablation
of Stat3 specifically in SCs increased their expansion during
regeneration, but compromised their myogenic differentiation
and prevented their contribution to regenerating myofibers
(Tierney et al., 2014). Intriguingly, transient inhibition of Stat3
function by pharmacological treatment led to an expansion of
SCs at a higher rate, and maintained their ability to differentiate
into fibers, thus enhancing tissue repair in both aged and
dystrophic muscle (Price et al., 2014; Tierney et al., 2014).
Recent findings have proposed a key role for BMPs in
controlling muscle mass. Unlike Myostatin signaling, BMP
acts through Smad1/5/8, eliciting a hypertrophic response in
muscle and involving the Akt pathway, the inhibition of which
by Rapamycin attenuates at least partially the BMP-mediated
response (Sartori et al., 2013;Winbanks et al., 2013). Inhibition of
BMP signaling causes muscle atrophy, abolishes the hypertrophic
phenotype of Myostatin-null mice, and exacerbates the effects
of denervation and fasting (Sartori et al., 2013; Winbanks et al.,
2013). The atrophic response observed after fiber-specific Smad4
conditional ablation suggests that BMPs regulate muscle mass by
directly acting on muscle fibers (Sartori et al., 2013). Indeed, the
degradation of muscle fiber proteins stimulated by the ubiquitin
ligase MUSA1 has been implicated in this process (Sartori et al.,
2013; Winbanks et al., 2013). Importantly, the inhibition of BMP
signaling not only counteracts the increase in muscle mass in
Myostatin-null mice, but also blunts the hypertrophic response
induced by Follistatin (Winbanks et al., 2013). Follistatin is a
powerful regulator of muscle mass, which exerts its function
mainly by inhibiting the action of Myostatin and Activins, both
of which are implicated as negative regulators of muscle growth
(Link and Nishi, 1997; Souza et al., 2008; Gilson et al., 2009;
Lee et al., 2010). Strikingly, the presence of SCs seems to be
required for a full Follistatin-dependent hypertrophy, as muscle
irradiation which abolishes the proliferative capacity of SCs
blunted the effects of Follistatin overexpression on muscle mass
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(Gilson et al., 2009). A caveat in this set of experiments is that
the use of electroporation to introduce Follistatin-expressing
plasmids into muscles is accompanied by a regenerative response
that almost certainly involves SC participation (Skuk et al., 2013).
Nevertheless, since Follistatin-induced hypertrophy is mitigated
by both the inhibition of BMP signaling as well as by blocking cell
proliferation, it is conceivable that BMP-mediated hypertrophy
is dependent on SC activity to a significant extent. Indeed, BMP
signaling strongly inhibits the myogenic differentiation program
in myogenic precursor cells, and is able to induce features typical
of the osteoblast lineage in myogenic cell lines under specific
in vitro conditions (Murray et al., 1993; Katagiri et al., 1994).
While there is a lack of evidence of the ability of SCs to commit
to the osteogenic program in vivo, several observations indicate
that BMP signaling plays an important role during muscle
regeneration by controlling myogenic progenitor differentiation
and positively modulating their proliferative expansion (Lounev
et al., 2009; Clever et al., 2010; Friedrichs et al., 2011; Ono et al.,
2011). Interfering with normal BMP signaling in vivo leads to
smaller regenerated fibers after muscle injury and to smaller
muscles during fetal development (Wang et al., 2010; Ono et al.,
2011). Together, these observations suggest that BMP signaling
occupies a central position in a complex network of signals that
control SC biology and muscle mass, besides being implicated in
the etiology of atrophy. These observations also support the idea
of an active cross-talk between different branches of the TGFβ
signaling pathway in the control of muscle mass.
An involvement of SCs in the control of muscle
mass is particularly relevant in diseases that continually
demand a damage-repair response from the tissue, such as
muscular dystrophies. Muscular dystrophies form a group
of heterogeneous genetic diseases, often characterized by
progressive muscle atrophy (Shin et al., 2013). Little is known
about the molecular changes occurring in SCs within the
dystrophic environment that prevents them from restoring
the growth of the atrophied muscles. Several members of the
TGFβ superfamily, including Myostatin, TGFβ1, and TGFβ2
have been implicated in the progression of different forms of
muscular dystrophy (Yamazaki et al., 1994; Bogdanovich et al.,
2002; Wagner et al., 2002; Andreetta et al., 2006; Onofre-Oliveira
et al., 2012; Biressi et al., 2014). Enhanced TGFβ signaling
appears to be responsible for the aberrant myogenic program
observed in the muscles of mdx mice (Biressi et al., 2014). TGFβ
signaling appears to alter SC function also in other diseases,
such as Emery-Dreyfuss muscular dystrophy (AD-EDMD), in
which mutations in the Lamin A/C genes cause muscle atrophy
and necrosis (Sewry et al., 2001). An analysis of SC activity
in the Lmna−/− mice revealed that the proliferation rates and
kinetics of activation of the SC progeny derived from Lmna−/−
muscles were slower and delayed compared to wild type muscles
(Cohen et al., 2013). More importantly, Lmna−/− myoblasts
displayed elevated levels of Smad2/3 that did not localize to
the nucleus in response to TGFβ stimulation. As a result, there
was an increase in cell death in myotube cultures, an event that
could contribute to wasting (Cohen et al., 2013). Additionally,
defective SC behavior, fiber atrophy, and enhanced TGFβ
signaling have also been observed in mouse models of Caveolin
3-deficient limb-girdle muscular dystrophy (Ohsawa et al.,
2012). Importantly, administration of an inhibitor of TGFβ type
I receptor not only ameliorates muscle atrophy, but also restores
the number and differentiation potential of SCs, indicating that
both TGFβ-dependent reduction in SCs and impaired myoblast
differentiation contribute to the cellular mechanism underlying
Caveolin 3-deficient muscle atrophy (Ohsawa et al., 2012).
A key modulator of TGFβ signaling in muscle and an
effector molecule of the renin-angiotensin system, Angiotensin
II (Ang II), has been implicated in muscle degeneration and
accumulation of fibrotic tissue in several congenital and acquired
muscle disorders (Cohn et al., 2007). In keeping with this, down-
regulation of TGFβ signaling by Ang II inhibitors ameliorates
muscle wasting in different myopathies (MacDonald and Cohn,
2012). Ang II is also involved in the etiology of cachexia, such
that patients with CKD and CHF often have elevated Ang II
levels, and treatment with an angiotensin converting enzyme
inhibitor can reduce weight loss (Anker et al., 2003). Consistent
with this notion, earlier studies showed that the infusion of Ang
II in rodents decreased muscle weights by increasing protein
degradation, disrupting IGF-1 signaling and inducing apoptosis
(Brink et al., 1996). In SCs, Ang II was demonstrated to impair SC
proliferation and differentiation by signaling events mediated by
one of its receptors, Angiotensin 1 (AT1R), during the course of
muscle regeneration (Yoshida et al., 2013). Indeed, by inhibiting
AT1R activity in CHF, a condition in which high Ang II levels
are present, the observed reduction in SC numbers and muscle
weight could be blocked (Yoshida et al., 2013). Intriguingly, an
opposite function was ascribed to Ang II Type 2 receptor (AT2R)
that is expressed in differentiating SC progeny and is known to
promote regeneration (Yoshida et al., 2014). These observations
highlight the importance of defining the mechanisms operating
downstream of atrophic signals, in order to develop therapeutic
approaches that are specific and effective.
Glucocorticoid and Androgen Signaling
Glucocorticoids, either in their synthetic or physiological
form, cortisol (in human) and corticosterone (in rodents),
have emerged as potent negative regulators of muscle mass
(Braun and Marks, 2015). Elevated levels of circulating
glucocorticoids have been linked to different atrophic conditions
including sepsis, diabetes, and cancer (Braun and Marks, 2015).
Glucocorticoids act by binding to glucocorticoid receptors, a
family of nuclear receptors, and exerting their function using
different mechanisms, including stimulating the expression
of muscle-specific E3 ubiquitin ligases in muscle fibers and
modulating the function of Akt, Myostatin, and multiple
other signaling pathways involved in the control of muscle
mass (Braun and Marks, 2015). By stimulating Myostatin
expression, glucocorticoids can also decrease SC proliferation
and differentiation (Dong et al., 2013).
Importantly, the effects of glucocorticoid administration on
muscle mass are counteracted by androgens in both patients
and animal models (Creutzberg et al., 2003; Eason et al.,
2003). Androgens are efficient positive modulators of muscle
mass and function by binding to the androgen receptor, also
a member of the nuclear receptor superfamily (Dubois et al.,
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2012). The androgen receptor is expressed not only in muscle
fibers, but also in SCs, in particular in the levator ani muscle,
a muscle that is dramatically affected in animal models with
a conditional ablation of androgen receptor expression in SCs
and fibers (Swift-Gallant and Monks, 2013; Dubois et al., 2014).
Several reports suggest that androgens are able to modulate gene
expression and function in SCs and myoblast cell lines (Chen
et al., 2005). Testosterone, the principal circulating androgen is
decreased in the serum of older men, possibly contributing to
the SC dysfunction observed in this condition (Yialamas and
Hayes, 2003). Intriguingly, the activation of SCs observed in
denervated levator ani muscle does not occur in castrated rats,
and this correlates with a reduction in myonuclear number
accompanying the atrophy observed in denervated muscles of
castrated rats (Nnodim, 1999). These observations suggest that at
least in specific muscles and under specific atrophic conditions,
the control of SC activity by androgens may contribute to fiber
homeostasis.
NF-κB Signaling
A large body of evidence has implicated the NF-κB transcription
factors as being major modulators of muscle mass (Li et al.,
2008; Peterson et al., 2011). When inactive, NF-κB is maintained
in the cytoplasm by a class of proteins called IκB. In response
to inflammatory cytokines, such as TNFα, IκB is degraded
leading to the nuclear translocation of NF-κB and activation
of NF-κB-dependent transcription (Li et al., 2008; Peterson
et al., 2011). An increase in NF-κB signaling has been reported
in the atrophic response associated with different disease
conditions. NF-κB signaling has been shown to mediate atrophy
by increasing the expression of components of the ubiquitin-
proteasome system, and by promoting the atrophic effects
of inflammation-related proteins (Li et al., 2008; Peterson
et al., 2011). More importantly, an increasing number of
observations suggest that NF-κB also regulates SC activity
in different atrophic conditions. Specifically, the presence of
systemic inflammation accompanying clinical features associated
with cachexia led to the discovery of a cytokine-induced up-
regulation of NF-κB signaling in the suppression of myogenic
gene expression in cell culture (Guttridge et al., 2000). Moreover,
a detailed examination of events within muscles from tumor-
bearing mice revealed that the induction of NF-κB activity
by cachectic serum contributed to Pax7 dysregulation in
muscle-resident progenitors, and was followed by a significant
decline in muscle mass (He et al., 2013). Although these
observations do not distinguish between increases in NF-
κB levels in SCs vs. fibers, there is a clear indication that
together with functioning as a potent modulator of muscle
regeneration and myogenic differentiation, NF-κB signaling
promotes atrophy, an effect which is achieved in part by
altering the behavior of SCs (Langen et al., 2001; Dogra et al.,
2006; Mourkioti et al., 2006; Wang et al., 2007; Bakkar et al.,
2008).
Sirt1 and Mitochondrial Dysfunction
Mitochondrial function and metabolism is crucial for SC
activation, proliferation, and for efficient muscle regeneration
(Jash and Adhya, 2012; Rodgers et al., 2014). A reduction
in mitochondrial mass, increased damage to mitochondrial
DNA, and increased levels of reactive oxygen species (ROS)
produced by the existing mitochondria were observed with
age (Minet and Gaster, 2012; Wang et al., 2013). Sirt1 is
a potent regulator of mitochondrial metabolism, displaying
altered expression in tumor-bearing animals and contributing
to reduced regeneration in muscle wasting (Toledo et al.,
2011). Intriguingly, an increase in Sirt1function is one of
the many outcomes of caloric restriction, that also include
an increase in SC proliferation, an increase in mitochondrial
abundance and an enhancement of the regenerative capacities
of muscles (Lee et al., 1998; Cohen et al., 2004; Cerletti et al.,
2012; McKiernan et al., 2012). These observations support a
possible role for Sirt1 in reducing muscle loss that occurs
with aging. Indeed, Sirt1 overexpression has been reported
to block fasting and denervation-induced fiber atrophy by
reducing FoxO activity (Lee and Goldberg, 2013). Moreover,
Sirt1 controls the transcription of peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC1α), which in
turn induces mitochondrial biogenesis and regulates peroxisome
proliferator-activated receptors gamma (PPARδ), a positive
regulator of SC proliferation (Amat et al., 2009; Angione et al.,
2011). Consistent with this observation, over-expression of Sirt1
increases the proliferation of myogenic progenitors (Rathbone
et al., 2009). Moreover, as a consequence of ablating Sirt1 in
SCs, myogenic progenitors undergo premature differentiation,
thereby negatively affecting muscle regeneration and growth
(Ryall et al., 2015). Although additional mechanistic studies are
required, this body of evidence suggests that the Sirt1-PGC1α
axis could ameliorate the loss of muscle mass at least in part by
improvingmitochondrial function and the regenerative potential
of SCs.
Notch Signaling
The importance of Notch signaling during muscle development
and regeneration has been well established (Luo et al., 2005;
Vasyutina et al., 2007a; Mourikis and Tajbakhsh, 2014).
Notch signaling plays an important role in maintaining
quiescence, proliferation, homing and self-renewal capabilities
of SCs (Conboy and Rando, 2002; Bjornson et al., 2012;
Bröhl et al., 2012; Mourikis et al., 2012b; Wen et al., 2012;
Gopinath et al., 2014). Notch signaling is essential to maintain
muscle progenitors during fetal development, to promote their
expansion, and to generate SCs (Vasyutina et al., 2007b;
Mourikis et al., 2012a). Indeed, developmental inactivation of
the Notch transcriptional complex by the selective ablation
of the Notch regulators, recombination signal binding protein
J (RBP-J) or mastermind-like (MAML1), specifically in the
myogenic compartment resulted in the reduction of muscle mass
(Vasyutina et al., 2007b; Lin et al., 2013).
Aging muscles consist of SCs with decreased regenerative
potential, which in turn is an outcome of reduced Notch
signaling, and can be restored by exposure to a young systemic
environment (Conboy et al., 2003, 2005). Intriguingly, it was
also reported that the consequences of Vitamin D depletion
in aged rats exacerbated the muscle loss associated with aging
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and was accompanied by reduced Notch activity in these
muscles (Domingues-Faria et al., 2014). At this point it remains
to be established whether Vitamin D exerts its effects on
skeletal muscle through the inhibition of the Notch signaling
pathway. Additionally, it remains to be demonstrated whether
enhancing Notch function in the Vitamin D-depleted aged rats
display possible beneficial effects on muscle mass, in addition
to the involvement of SCs in this context. Intriguingly, the
observation that Notch activation was able to abrogate the
inhibitory effects of the cachectic factor Ang ll on proliferation
of myogenic progenitors in culture raises the possibility of
using positive modulators of Notch signaling to boost SC
proliferation and counteract muscle loss (Yoshida et al.,
2013).
However, recent literature suggests that the outcome of
manipulating Notch activity has been met with incongruous
results. Using a Notch reporter mouse, it was demonstrated
that SCs isolated from mdx mice displayed reduced activation
of Notch signaling, and that constitutive Notch activation
could at least in part rescue the self-renewal deficit observed
in mdx SCs, without ameliorating muscle pathology associated
with these dystrophic mice (Jiang et al., 2014). On the other
hand, a recent study observed that acute manipulation of
Notch signaling by the injection of activators or inhibitors
did not affect muscle mass or maximal force in mdx mice,
as well as mice that were double-deficient for Utrophin
and Dystrophin (Church et al., 2014). These observations
suggest that while SCs display a stage-specific requirement
for Notch signaling, dystrophic muscles present a complex
environment with SCs at different stages of progression
and consequently exhibit different responses to Notch
manipulation that may not contribute to a net increase in
muscle weight. These studies underscore the importance of not
only investigating specific signaling pathways in the context of
specific forms of atrophy, but also addressing the efficacy of
manipulating a particular signaling mechanism for therapeutic
purposes.
Reversal of Atrophy: A Role for SCs?
The primary objective of obtaining a comprehensive
understanding of the mechanistic processes underlying atrophy
in a manner that discerns molecular changes in SCs from those
in fibers, is to address whether manipulating these signaling
mechanisms can enhance the participation of SCs in restoring
muscle mass. In this section, we review those studies in which
SC activity has been modulated to expand their functionality
in muscle wasting accompanying chronic diseases. Broadly,
the focus of these interventions has been signaling pathways
that modulate SC proliferation, differentiation, senescence and
survival.
In muscle wasting accompanying COPD, patients experience
decreased oxygen saturation level (hypoxemia) that can elicit
hypoxic responses in tissues (Wüst and Degens, 2007). This
includes an impairment in anabolic pathways, decrease in food
intake by the induction of leptin, and muscle disuse that are
directly responsible for a loss in muscle mass (Wüst and Degens,
2007). In studies aimed to increase the protein synthesis pathway
in SCs under conditions of hypoxia-induced atrophy, a regimen
of alternating treatments with hepatocyte growth factor (HGF)
and leukemia inhibitory factor (LIF) not only increased SC
proliferation, but also increased the cross sectional area of fibers
and total muscle weight (Hauerslev et al., 2014). Corroborating
these results in normoxic mice, this growth factor treatment
promoted SC proliferation and increased the weight of the
tibialis anterior muscle in mice deleted for Myostatin expression
(Hauerslev et al., 2014). These results further highlight the
potential of exploringMyostatin regulation in SCs for therapeutic
purposes in combatting atrophy.
Strategies aimed at enhancing SC proliferation to increase
their participation in muscle mass restoration have been
particularly useful in limb-girdle muscular dystrophy type 1B
(LGMD1B) and AD-EDMD forms of dystrophies. Under these
conditions, increased levels of lamina-associated polypepetide
alpha (Lap2α), a protein that interacts with Lamin A/C
and phosphorylated Rb has been implicated in reducing SC
proliferation (Mancini et al., 1994; Ozaki et al., 1994). Since the
Lap2α−/− cells are hyperproliferative due to a defect in cell cycle
exit, the authors created a Lmna−/− Lap2α−/− double KO mice
to enhance SC proliferation, thereby resulting in an increase
in the fusion index and overall muscle size of the double KOs
(Cohen et al., 2013). This study not only offers valuable insights
into the etiology of laminopathies but also provides alternate
strategies using SCs for therapeutic intervention.
Contrary to the atrophic conditions discussed above, the
increase in SC numbers in the interstitium in cancer-induced
cachexia prompted the use of mutant mouse models to inactivate
Pax7 expression in tumor-bearing mice (He et al., 2013).
Not only did this cause a reversal of wasting by promoting
cell differentiation and fusion with injured fibers, but also
demonstrated that impaired myogenic progression by sustained
Pax7 expression was the primary cause for muscle wasting
in these mice, and offered the attractive possibility of gene
therapy approaches to modulate Pax7 expression (He et al.,
2013). In particular, the identification of regulators that repress
Pax7 expression to limit its window of action and allow for
myogenic progression during the course of normal regeneration
can be potentially exploited for therapeutic purposes. Indeed,
the activation of the Polycomb Repressive Complex 2 (PRC2) by
p38α kinase results in the formation of repressive chromatin on
the Pax7 locus, thereby providing an additional interventional
target that could be explored in a tumor-promoting milieu
(Palacios et al., 2010).
In disuse atrophy, the focus of various interventional studies
have been on regulators that enhance SC functionality and
increase muscle growth, especially in the subsequent recovery
phase. In a recent study, E3 ubiquitin ligase tripartite motif-
containing 32 (TRIM32) was demonstrated to be essential
for the selective regrowth of Type 2 fast fibers after hind
limb suspension-induced atrophy (Kudryashova et al., 2012).
TRIM32-deficient myoblasts displayed impaired differentiation,
and elevated levels of senescence-associated β-galactosidase (β-
gal; Kudryashova et al., 2012). Premature senescence of SCs was
also demonstrated to be the underlying cause for the pathogenic
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features associated with limb-girdle muscular dystrophy 2H
(LGMD2H), that arise frommutations in TRIM32 (Saccone et al.,
2008; Cossée et al., 2009). These studies suggested that unlike
other E3 ubiquitin ligases that promote atrophy, TRIM32 might
possess a unique function of preventing premature senescence
in SCs, thereby enhancing muscle growth. Although these
speculations support the idea of an involvement of SCs, more
investigations are required to explore the mechanisms by which
TRIM32 could promote regrowth after atrophy. Indeed, the
extent to which SCs are required in the process of recovery
from hind limb suspension is still unclear. Ablation studies
indicate that muscle mass recovery after hind limb suspension
could also occur in the absence of SCs (Jackson et al., 2012).
Nevertheless, during the recovery phase of soleus muscle mass
upon its reloading, the decrease in myonuclear content derived
from hind limb unloading was restored to control levels,
suggesting that myogenic precursor cells can proliferate and
fuse with myofibers during the recovery process (Mitchell and
Pavlath, 2001). Moreover, after an initial phase of muscle
regrowth, inhibiting the proliferation ofmuscle precursor cells by
irradiation prevented a full recovery (Mitchell and Pavlath, 2001).
As such, it would be crucial to quantify the relative contributions
of SC-mediated and myofiber-mediated processes, in addition
to investigating molecular events that distinguish between SC-
intrinsic and fiber-intrinsic processes during muscle recovery.
IGF-1 is another factor that has been shown to modulate
SC activity and has been reported to be beneficial in promoting
regrowth after muscle unloading. In a study aimed to investigate
the effects of IGF-1 overexpression on the recovery of muscle
size during ambulation after cast immobilization, it was observed
that viral-mediated IGF-1 transfer to skeletal muscle enhanced
regeneration (Stevens-Lapsley et al., 2010). Intriguingly, IGF-1
overexpression did not protect against cast immobilization-
induced muscle atrophy, indicating that there are different
mechanisms regulating muscle mass during unloading and
reloading (Stevens-Lapsley et al., 2010). Delivery of IGF-1
into muscle and muscle-specific overexpression of IGF-1 were
also beneficial in ameliorating sarcopenia and stimulating
recovery in immobilized old muscles (Barton-Davis et al., 1998;
Chakravarthy et al., 2000; Musarò et al., 2001). Moreover,
increased levels of IGF-1 in muscle has been shown to control SC
activity and reduce muscle wasting in different genetic disorders,
including muscular dystrophy and amyotrophic lateral sclerosis
(ALS; Barberi et al., 2009).
A crucial aspect underlying the enhancement of SC
functionality for cellular therapy is the investigation of
mechanisms that specifically promote cell survival without
affecting proliferation, in order to avoid the risk of cancer-
promoting effects. A growth factor-derived engineered protein,
Magic-Factor 1 (or Met-Activating Genetically Improved
Chimeric Factor 1), has been developed to elicit the activation of
the Akt survival pathway, but not the mitogenic ERK pathway.
Magic-Factor 1 decreased the expression of Myostatin and
apoptotic markers in myogenic cells in vitro. Consistent with
these observations, Magic-Factor 1 promoted survival and
differentiation (Cassano et al., 2008). Moreover, transgenic
mice expressing muscle-specific Magic-factor 1 displayed
hypertrophic fast twitch fibers with increased endurance to
exercise, in addition to partially rescuing the degeneration
observed in α-sarcoglycan KO mice (Cassano et al., 2008).
Thus, tissue-specific engineered proteins hold potent clinical
applications for ameliorating muscle wasting associated with
dystrophies.
In addition to modulating specific signaling pathways,
exercise and electrical stimulation appear to be promising
therapeutic approaches in countering atrophy. Exercise has been
proven to be effective in reducing muscle loss and in mobilizing
SCs in aging muscles (Snijders et al., 2009). Concomitant to
the increase in SC content, an up-regulation of myogenic
regulatory factors and a reduction in Myostatin expression have
been observed (Snijders et al., 2009). The beneficial effects of
exercise have also been reported in disuse atrophy occurring
with immobilization, and correlate with an increase in IGF-1
and Myogenin, and a decrease in Myostatin levels (Adams
et al., 2007). Recent reports have demonstrated that the decrease
in muscle size and SC number occurring during hind limb
unloading could also be attenuated by electrical stimulation
(Zhang et al., 2010b; Guo et al., 2012; Dirks et al., 2014). Although
a causal relationship between SC activation and an attenuation
in atrophy remain to be fully established, it seems that electrical
stimulation can modify SC activity and prove beneficial to other
forms of atrophy such as sarcopenia (Kern et al., 2014).
Another promising approach to ameliorate loss of muscle
mass is cell therapy. Transplantation of SCs and other cellular
types capable of myogenic differentiation have been shown to
improve muscle phenotypes associated with different primary
genetic diseases, especially in muscular dystrophies. In most of
these studies, the rational of the cell therapy approach involves
using cells to carry therapeutic genes into myofibers (Partridge
and Davies, 1995). After transplantation, healthy donor-derived
or patient-derived corrected cells fuse with existing myofibers
and correct for the absence of expression from the mutated
gene. The efficacy of this approach lies in the ability of the
transplanted cells to not only differentiate into myofibers, but
also to replenish the reservoir of stem cells and thereby sustain
the repair process. Several studies have been exploring the
potential of other stem cells besides SCs for therapeutic purposes
(Peault et al., 2007). A complete and exhaustive discussion
of these studies is beyond the scope of the present report
and the readers are directed to comprehensive reviews that
extensively describe cell transplantation approaches in primary
genetic myopathies (Skuk and Tremblay, 2003; Price et al.,
2007; Quattrocelli et al., 2010; Tedesco et al., 2010; Meng et al.,
2011; Meregalli et al., 2013; Sirabella et al., 2013). We focus in
this paragraph on acquired muscle wasting conditions. Recent
observations suggest that a cell transplantation approach could
be useful in reducing muscle loss after hind limb suspension
and denervation (Plowman et al., 2014; Kim et al., 2015).
Importantly, it has been reported that transplantation of SCs
attached to their myofiber coupled with muscle injury could
prevent the loss of muscle mass associated with aging (Hall
et al., 2010). Intriguingly, transplantation in the absence of injury
did not result in a similar increase in muscle mass (Hall et al.,
2010). The interpretation of this observation is confounded by
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the high rate of lethality of donor cells generally associated
with transplantation (Beauchamp et al., 1999). Nevertheless it
supports the hypothesis that the authors of this study propose
that unknown factors produced during injury can signal to
fiber-associated SCs, and promote their long-term engraftment
and hypertrophic function (Hall et al., 2010). In these set of
experiments, fiber-associated SCs were transplanted intomuscles
of young mice and an increase in muscle mass was observed
in 2-year-old mice (Hall et al., 2010). However, it remains to
be tested whether heterologous transplantation of young fiber-
associated SCs into injured muscles of old mice would also be
beneficial in ameliorating sarcopenia. A large body of evidence
indicates that during aging, local and systemic environments
undergo profound changes that bear a negative impact onmuscle
precursor cell activity and regenerative potential (Gopinath
and Rando, 2008), thus proving to be a major hurdle in
transplantation approaches in aged muscles. Intriguingly, a
recent study demonstrated that inhibiting p38α and p38β
signaling transiently in myogenic progenitors isolated from aged
mice, in conjunction with culture on soft hydrogel substrates
rejuvenates their regenerative potential and increases muscle
strength upon transplantation into damaged muscles of aged
mice (Cosgrove et al., 2014). Although it is not clearly understood
as to how these mechanisms enhance the regenerative capacity of
old SCs, these observations suggest that the detrimental effects
of an aging muscle microenvironment can be circumvented.
Changes in the local and systemic environments are not a feature
of aging alone, but are also profoundly altered in other chronic
muscle wasting conditions, such as cancer cachexia (He et al.,
2013). Future studies will be required to evaluate the efficacy
of cell transplantation approaches in ameliorating muscle loss
under various atrophic stimuli.
Concluding Remarks
In conclusion, it is becoming increasingly evident that
understanding the basic molecular mechanisms underlying
various forms of atrophy is crucial to develop defined parameters
and describe distinct features that categorize different forms of
atrophy. It is also possible that different forms of atrophy could
co-exist, such as disuse atrophy that accompanies aging coupled
to bedridden conditions, as a result of chronic debilitating
illnesses. Moreover, aging is a risk factor for many pathologies
impacting muscle mass (Evans, 1995). Such multiple cause-
related atrophies warrant the use of combinatorial therapies that
selectively target the signaling pathway or pathways involved
in specific atrophic processes. It has also become significantly
clear that SC-focused studies expand the approaches that can
be used to counter muscle loss. In general, despite a large body
of evidence in favor of a role for SCs at least in some forms
of atrophy, there have been reports that have restricted and
thereby defined the window of SC action, or have evaluated SC
functionality quantitatively rather than qualitatively. As such,
these studies may have contributed to the ‘‘quasi-status’’ of
SC involvement in atrophy. This, in addition to a knowledge
of the molecular and cellular changes in SCs accompanying
atrophy offer a powerful tool in being able to manipulate this
compartment pharmacologically to increase muscle mass. In this
context, SC-specific gene ablation studies in mice would provide
a promising avenue to uncover novel signaling networks and
thereby adopt a more focused approach towards tackling muscle
wasting diseases in humans. These studies are currently being
limited by difficulties in achieving a complete ablation of genes
in a SC-specific manner, and the development of highly efficient
strategies will be key in obtaining an accurate assessment of
the requirement of the candidate genes during atrophy. A
corollary to this approach is a comprehensive understanding
of the systemic factors and the molecular milieu constituting
the SC niche in the context of various atrophic conditions. In
providing the means to modulate and eventually enhance SC
function, this area of study renders itself to alternate therapeutic
strategies such as nutritional interventions, other than exercise
or pharmacological-based solutions (Alway et al., 2014). This
is especially relevant in aging individuals with unrelated
muscle wasting pathologies, wherein there are considerable
limitations during the course of treatment. This shift in focus
of examining molecular events during atrophy from fiber to
SCs can potentially further be exploited even in scenarios that
have reported limited involvement of the SC compartment in
restoring muscle mass. A critical discussion of the cellular and
molecular events operating in the atrophying muscles and SCs
will contribute to the field for further studies investigating novel
approaches to ameliorate muscle wasting diseases.
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